InvestWiser

Ascelia Pharma AB (publ)

ACENasdaq StockholmHealthcareMarket value 80 m SEK
0.60SEK −4.3%
last day · Price as of 18 November 2026

The answer first

Does Ascelia Pharma beat the market?

No, Ascelia Pharma has not beaten the market over the last year.

Ascelia Pharma−78.7%Stockholm (OMXSGI)+18.7%
  • The ranking · Quality, value and trend combined

    Better than 16% of Nordic stocks

    • Quality69
    • Value13
    • Trend13

    No. 144 of 195 in healthcare

Max for seven days

Follow Ascelia Pharma with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Ascelia Pharma

From today, at a price of 0.60 SEK. Write why you follow Ascelia Pharma, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Ascelia Pharma

Your first answer is free, no account needed.

Do you own Ascelia Pharma, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Ascelia Pharma and a few more. Free, no card.

Past year against the exchange and Super Stock
Ascelia Pharma−78.7%Stockholm (OMXSGI)+18.7%Super Stock+45.9%
17 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Ascelia Pharma has fallen 78.7% over the past year, including dividends.
  • Overall, Ascelia Pharma ranks better than 16% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 97.1%. The price is 99.1% below its peak now.

What do analysts think of Ascelia Pharma?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

16

Quality, value and trend together. Better than 16% of Nordic stocks.

No. 144 of 195 in healthcare

Quality69
The company · Fundamentals: the accounts

High A solid company: it earns well on its money and has healthy finances.

No. 86 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.01
  • Asset turnoverSales divided by everything the company owns0.00
  • Return on equityProfit divided by equity−68.7%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value13
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 126 of 197 in healthcareTypical in healthcare: 21Typical in the Nordics: 50

  • P/BPrice divided by equity1.0
  • P/SPrice divided by sales–
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend13
The share price · Technical: the price trend

Low Headwind in the share price: it has done worse than most over the last year.

No. 148 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−2.7%
  • 6 months−80.1%
  • 9 months−81.4%
  • 12 months−78.7%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
+15.4%
3 years, per year
−41.6%
5 years, per year
−54.0%
Year to date
−81.4%
Largest fall, 3 years
−97.1%
From a peak to the bottom
From the peak now
−99.1%
How far the price is from the peak
Volatility, 1 year
107.8%
How much the price swings over a year
Beta, 1 year
0.28
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own Ascelia Pharma

4 funds we follow own Ascelia Pharma. The share is how much of the fund the stock makes up.

  • Sweden4

From the funds' latest known holdings.

About Ascelia Pharma

Ascelia Pharma AB (publ) is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 10 employees.

Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. The company was incorporated in 1999 and is headquartered in Malmö, Sweden.

See the full analysis of Ascelia Pharma.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market